載入中
Ocugen, Inc. is a biopharmaceutical company in the clinical development phase, primarily dedicated to pioneering gene therapies aimed at treating various ophthalmic conditions leading to blindness. The company's developmental pipeline features several key candidates: OCU400: An innovative gene therapy designed to reinstate both the function and structural integrity of the retina across a broad spectrum of genetically diverse inherited retinal diseases, such as retinitis pigmentosa and Leber congenital amaurosis. OCU410: Another gene therapy candidate, currently being developed to address dry age-related macular degeneration (AMD). OCU200: A novel fusion protein, presently undergoing preclinical evaluation for its potential in treating diabetic macular edema, diabetic retinopathy, and wet AMD. Ocugen maintains significant strategic collaborations, including a partnership with CanSino Biologics Inc. for the joint development and manufacturing of gene therapies, and an alliance with Bharat Biotech for the commercialization of COVAXIN within the United States market. The company's corporate headquarters are situated in Malvern, Pennsylvania.
收盤時
US$0.9472
−US$0.0083 · -0.87%
盤後
US$0.942
−US$0.0052 · -0.55%
10月12日 下午7:51 ET
盤中時間採用ET。市場資料可能有所延遲。
Ocugen, Inc. is a biopharmaceutical company in the clinical development phase, primarily dedicated to pioneering gene therapies aimed at treating various ophthalmic conditions leading to blindness. The company's developmental pipeline features several key candidates: OCU400: An innovative gene therapy designed to reinstate both the function and structural integrity of the retina across a broad spectrum of genetically diverse inherited retinal diseases, such as retinitis pigmentosa and Leber congenital amaurosis. OCU410: Another gene therapy candidate, currently being developed to address dry age-related macular degeneration (AMD). OCU200: A novel fusion protein, presently undergoing preclinical evaluation for its potential in treating diabetic macular edema, diabetic retinopathy, and wet AMD. Ocugen maintains significant strategic collaborations, including a partnership with CanSino Biologics Inc. for the joint development and manufacturing of gene therapies, and an alliance with Bharat Biotech for the commercialization of COVAXIN within the United States market. The company's corporate headquarters are situated in Malvern, Pennsylvania.
日內區間
目前US$0.9472
52週區間
目前US$0.9472
盤中時間採用ET。市場資料可能有所延遲。
Ocugen, Inc. is a biopharmaceutical company in the clinical development phase, primarily dedicated to pioneering gene therapies aimed at treating various ophthalmic conditions leading to blindness. The company's developmental pipeline features several key candidates: OCU400: An innovative gene therapy designed to reinstate both the function and structural integrity of the retina across a broad spectrum of genetically diverse inherited retinal diseases, such as retinitis pigmentosa and Leber congenital amaurosis. OCU410: Another gene therapy candidate, currently being developed to address dry age-related macular degeneration (AMD). OCU200: A novel fusion protein, presently undergoing preclinical evaluation for its potential in treating diabetic macular edema, diabetic retinopathy, and wet AMD. Ocugen maintains significant strategic collaborations, including a partnership with CanSino Biologics Inc. for the joint development and manufacturing of gene therapies, and an alliance with Bharat Biotech for the commercialization of COVAXIN within the United States market. The company's corporate headquarters are situated in Malvern, Pennsylvania.
日內區間
目前US$0.9472
52週區間
目前US$0.9472
獲利能力占已公布營收的百分比。
營收
營業利益
淨利
| 項目（USD） | 2025會計年度 | 2024會計年度 | 2023會計年度 | 2022會計年度 | 2021會計年度 |
|---|---|---|---|---|---|
| 營收 | 441.3萬 USD | 405.5萬 USD | 603.6萬 USD | 248.8萬 USD | — |
| 銷貨成本 | 238.9萬 USD | 196.8萬 USD | 70.4萬 USD | — | — |
| 毛利 | 202.4萬 USD | 208.7萬 USD | 533.2萬 USD | 248.8萬 USD | — |
| 研究與開發 | 3975萬 USD | 3212.6萬 USD | 3957.3萬 USD | 5615.9萬 USD | 3510.8萬 USD |
| 銷售、一般及管理費用 | 2757.9萬 USD | 2668.6萬 USD | 3199.4萬 USD | 3540萬 USD | 2292萬 USD |
| 營業費用 | 6494萬 USD | 5684.4萬 USD | 7086.3萬 USD | 9155.9萬 USD | 5802.8萬 USD |
| 利息收入 | 92.2萬 USD | 130萬 USD | 250萬 USD | 140萬 USD | — |
| 利息支出 | 518.8萬 USD | — | — | — | 7.9萬 USD |
| 折舊和攤銷 | 238.9萬 USD | 196.8萬 USD | 70.4萬 USD | 48萬 USD | 22.9萬 USD |
| 營業利益 | −6291.6萬 USD | −5475.7萬 USD | −6553.1萬 USD | −8907.1萬 USD | −5802.8萬 USD |
| 淨利 | −6784.6萬 USD | −5405.4萬 USD | −6307.8萬 USD | −8680.4萬 USD | −5836.5萬 USD |
公司資料更新於 2026年10月13日。
近期已公布業績
近期已公布業績
第三方分析師預期可能變動，並非 GoAI 建議。
平均目標
US$5.00
上漲空間 427.87%| 行動 | 生效日期 | 詳情 | 記錄日期 | 付款日期 |
|---|---|---|---|---|
股票分割 | 2019年9月30日 | 1:60 | — | — |
已生效 2019年9月30日
1:60
報告持有此股票曝險的交易所交易基金。
Vanguard Morningstar Total Stock Market ETFVTI1353.55萬0.00%2.3兆 USD0.03%US$381.57-0.10%
State Street SPDR S&P Biotech ETFXBI1018.81萬0.10%103.03億 USD0.35%US$151.4-1.54%
iShares Russell 2000 ETFIWM863.23萬0.01%787.4億 USD0.19%US$277.9-0.37%
Vanguard Extended Market ETFVXF523.02萬0.01%954億 USD0.05%US$233.52-0.63%
Vanguard Russell 2000 ETFVTWO261.26萬0.01%180億 USD0.06%US$112.27-0.35%
iShares Russell 2000 Growth ETFIWO210.34萬0.02%139.17億 USD0.24%US$353.71-0.86%
State Street SPDR S&P Kensho New Economies Composite ETFKOMP171.52萬0.07%26.34億 USD0.20%US$65.26-1.64%
Vanguard Health Care ETFVHT132.89萬0.01%220億 USD0.09%US$320.67+0.52%Vanguard Morningstar Total Stock Market ETFVTIState Street SPDR S&P Biotech ETFXBIiShares Russell 2000 ETFIWMVanguard Extended Market ETFVXFVanguard Russell 2000 ETFVTWOiShares Russell 2000 Growth ETFIWOState Street SPDR S&P Kensho New Economies Composite ETFKOMPVanguard Health Care ETFVHTAI 生成內容及延遲市場資料僅供資訊與教育用途，不構成投資建議。
